It has been reported that knockdown of KITLG with siRNA and inhibition of SCF signaling by tyrosine kinase inhibitors like sorafenib could enhance anti-tumor reactivity, tumor regression and prolonged survival in murine models of colon and Lewis lung carcinoma36, 37, and we firstly identified the KITLG gene was a novel OCT4-responsive gene that was upregulated upon wild-type OCT4 overexpression. This evidence concerns the gene KITLG and neoplasm.